Drugs for Neurogenic Bladder Dysfunction
Urinary dysfunction includes an overactive bladder (OAB), post-void residual (PVR)/retention, or both entities. Brain diseases cause OAB, peripheral neuropathies are associated with significant PVR/retention, and multisystem atrophy/spinal cord diseases result in a combination of OAB and PVR/retention. Selective beta 3 adrenergic receptor agonists or anticholinergic agents are the first-choice treatment for OAB and clean intermittent self-catheterization, alpha-blocker and cholinergic stimulant therapy for significant PVR/retention. These therapies may be useful to maximize patients' quality of life and prevent serious complications, such as urosepsis or kidney dysfunction.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
|---|---|
| Enthalten in: |
Brain and nerve = Shinkei kenkyu no shinpo - 75(2023), 5 vom: 17. Mai, Seite 623-629 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Sakakibara, Ryuji [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenergic alpha-Antagonists |
|---|
| Anmerkungen: |
Date Completed 31.10.2023 Date Revised 31.10.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.11477/mf.1416202388 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356971287 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356971287 | ||
| 003 | DE-627 | ||
| 005 | 20231226071602.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.11477/mf.1416202388 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1189.xml |
| 035 | |a (DE-627)NLM356971287 | ||
| 035 | |a (NLM)37194541 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Sakakibara, Ryuji |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drugs for Neurogenic Bladder Dysfunction |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.10.2023 | ||
| 500 | |a Date Revised 31.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Urinary dysfunction includes an overactive bladder (OAB), post-void residual (PVR)/retention, or both entities. Brain diseases cause OAB, peripheral neuropathies are associated with significant PVR/retention, and multisystem atrophy/spinal cord diseases result in a combination of OAB and PVR/retention. Selective beta 3 adrenergic receptor agonists or anticholinergic agents are the first-choice treatment for OAB and clean intermittent self-catheterization, alpha-blocker and cholinergic stimulant therapy for significant PVR/retention. These therapies may be useful to maximize patients' quality of life and prevent serious complications, such as urosepsis or kidney dysfunction | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Adrenergic beta-3 Receptor Agonists |2 NLM | |
| 650 | 7 | |a Cholinergic Antagonists |2 NLM | |
| 650 | 7 | |a Adrenergic alpha-Antagonists |2 NLM | |
| 700 | 1 | |a Sawai, Setsu |e verfasserin |4 aut | |
| 700 | 1 | |a Ogata, Tsuyoshi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Brain and nerve = Shinkei kenkyu no shinpo |d 2007 |g 75(2023), 5 vom: 17. Mai, Seite 623-629 |w (DE-627)NLM168920336 |x 1881-6096 |7 nnns |
| 773 | 1 | 8 | |g volume:75 |g year:2023 |g number:5 |g day:17 |g month:05 |g pages:623-629 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.11477/mf.1416202388 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 75 |j 2023 |e 5 |b 17 |c 05 |h 623-629 | ||